A Phase IV, Two-Arm, Open-Label, Single-Centre Randomised Pilot Study to Assess the Feasibility of Immediate or Deferred Switching of HIV-Infected Individuals Intolerant of Efavirenz, Ritonavir-Boosted Lopinavir or Ritonavir-Boosted Darunavir.

Trial Profile

A Phase IV, Two-Arm, Open-Label, Single-Centre Randomised Pilot Study to Assess the Feasibility of Immediate or Deferred Switching of HIV-Infected Individuals Intolerant of Efavirenz, Ritonavir-Boosted Lopinavir or Ritonavir-Boosted Darunavir.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 05 Dec 2012

At a glance

  • Drugs Darunavir (Primary) ; Ritonavir
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Nov 2010 Status changed from recruiting to discontinued due to difficulties in recruitment due to a change in the nature of practice, according to ClinicalTrials.gov.
    • 20 Nov 2009 Planned end date changed from 1 Jun 2009 to 1 Jun 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top